EA201990784A1 - ANTI-MUC16 (MUCIN16) ANTIBODIES - Google Patents
ANTI-MUC16 (MUCIN16) ANTIBODIESInfo
- Publication number
- EA201990784A1 EA201990784A1 EA201990784A EA201990784A EA201990784A1 EA 201990784 A1 EA201990784 A1 EA 201990784A1 EA 201990784 A EA201990784 A EA 201990784A EA 201990784 A EA201990784 A EA 201990784A EA 201990784 A1 EA201990784 A1 EA 201990784A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- muc16
- antigen binding
- antibodies
- useful
- bispecific
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Муцин 16 (MUC16) экспрессируется на высоком уровне при раке яичников, и показано, что экспрессия на раковых клетках защищает опухолевые клетки от иммунной системы. Данное изобретение относится к новым полноразмерным человеческим антителам IgG, которые связываются с MUC16 человека (моноспецифические антитела). Данное изобретение также относится к новым биспецифичным антителам (бсАт), которые связываются как с MUC16, так и с CD3 и активируют T-клетки через CD3 комплекс в присутствии опухолей, экспрессирующих MUC16. Согласно определенным вариантам осуществления данное изобретение относится к биспецифичным антигенсвязывающим молекулам, содержащим первый антигенсвязывающий домен, который специфически связывает CD3 человека и обезьяны, и вторую антигенсвязывающую молекулу, которая специфически связывает MUC16 человека и обезьяны. В определенных вариантах осуществления изобретения указанные биспецифичные антигенсвязывающие молекулы по данному изобретению способны ингибировать рост опухолей, экспрессирующих MUC16. Биспецифичные антигенсвязывающие молекулы по данному изобретению полезны для лечения заболеваний и расстройств, при которых усиленный или индуцированный MUC16-направленный иммунный ответ является желательным и/или терапевтически полезным. Например, биспецифичные антитела по данному изобретению полезны для лечения различных видов рака, включая рак яичников. Данное изобретение также включает конъюгаты анти-MUC16 антитела с лекарственным средством, которые ингибируют рост опухоли in vivo. В некоторых вариантах осуществления изобретения указанные анти-MUC16 антитела полезны в диагностических способах для выявления присутствия MUC16 в образцах ткани и/или плазмы.Mucin 16 (MUC16) is highly expressed in ovarian cancer, and it has been shown that expression on cancer cells protects tumor cells from the immune system. This invention relates to new full-sized human IgG antibodies that bind to human MUC16 (monospecific antibodies). This invention also relates to new bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells through the CD3 complex in the presence of tumors expressing MUC16. In certain embodiments, the invention provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human and monkey CD3, and a second antigen binding molecule that specifically binds human and monkey MUC16. In certain embodiments of the invention, said bispecific antigen binding molecules of the invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen binding molecules of this invention are useful for treating diseases and disorders in which an enhanced or induced MUC16-directed immune response is desirable and / or therapeutically useful. For example, the bispecific antibodies of this invention are useful for treating various types of cancer, including ovarian cancer. The invention also includes anti-MUC16 antibody conjugates with a drug that inhibit tumor growth in vivo. In some embodiments, said anti-MUC16 antibodies are useful in diagnostic methods for detecting the presence of MUC16 in tissue and / or plasma samples.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558711P | 2017-09-14 | 2017-09-14 | |
| PCT/US2017/053114 WO2018058003A1 (en) | 2016-09-23 | 2017-09-22 | Anti-muc16 (mucin 16) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990784A1 true EA201990784A1 (en) | 2019-09-30 |
Family
ID=68000230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990784A EA201990784A1 (en) | 2017-09-14 | 2017-09-22 | ANTI-MUC16 (MUCIN16) ANTIBODIES |
| EA201990779A EA039842B1 (en) | 2017-09-14 | 2017-09-22 | Bispecific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990779A EA039842B1 (en) | 2017-09-14 | 2017-09-22 | Bispecific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
Country Status (1)
| Country | Link |
|---|---|
| EA (2) | EA201990784A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3271398B1 (en) * | 2015-03-17 | 2022-08-31 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| EP3353212B1 (en) * | 2015-09-23 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
-
2017
- 2017-09-22 EA EA201990784A patent/EA201990784A1/en unknown
- 2017-09-22 EA EA201990779A patent/EA039842B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA039842B1 (en) | 2022-03-18 |
| EA201990779A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500604A1 (en) | Anti-muc16 (mucin 16) antibodies | |
| EA201990781A1 (en) | ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION | |
| MY195059A (en) | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof | |
| PH12021550031A1 (en) | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF | |
| JOP20160154B1 (en) | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof | |
| EA201691858A1 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
| EA202191580A1 (en) | SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION | |
| CY1119454T1 (en) | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
| EA201590613A1 (en) | ANTIBODIES AGAINST CD3, BISPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO CD3 AND CD20, AND THEIR APPLICATIONS | |
| UA99701C2 (en) | Human monoclonal antibody that specifically binds to programmed death ligand 1 (pd-l1) | |
| EA201991763A1 (en) | CCR7 ANTIBODY AND MEDICINE CONJUGATES | |
| CY1123926T1 (en) | ANTIBODIES AGAINST TRANSGLUTAMINASE 2 | |
| MX2020011487A (en) | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof. | |
| MX2019011520A (en) | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof. | |
| EA201990784A1 (en) | ANTI-MUC16 (MUCIN16) ANTIBODIES | |
| MX2021003756A (en) | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies. | |
| EA202190314A1 (en) | BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION | |
| MX2022008745A (en) | ANTI-NKp30 ANTIBODIES AND METHODS OF USE. | |
| MA46281B1 (en) | Anti-muc16 antibodies (mucin 16) | |
| EA202090303A3 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
| EA201991227A1 (en) | ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 | |
| EA201991070A1 (en) | BINDING MOLECULES SPECIFIC TO ASCT2 AND THEIR APPLICATIONS |